Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach (Q38119146)

29 August 2017

Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach (English)

1 reference

29 August 2017

Yao Dai

1

1 reference

29 August 2017

Dongsheng Dai

2

1 reference

29 August 2017

Federico Mercanti

3

1 reference

29 August 2017

Zufeng Ding

4

1 reference

29 August 2017

Xianwei Wang

5

1 reference

29 August 2017

Jawahar L Mehta

6

1 reference

29 August 2017

4 July 2013

1 reference

29 August 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Acta Diabetologica

1 reference

29 August 2017

50

1 reference

29 August 2017

827-835

1 reference

29 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s00592-013-0496-4

29 August 2017

0 references

cites work

Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor gamma coactivator 1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Rhythm control versus rate control for atrial fibrillation and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Incretin-based therapies and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

GLP-1 receptor agonists: a clinical perspective on cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Exenatide exerts a potent antiinflammatory effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Effects of ACE inhibitor and beta-adrenergic blocker on plasma NPY and NPY receptors in aortic vascular smooth muscle cells from SHR and WKY rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Restoring stem cell mobilization to promote vascular repair in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Diabetes impairs stem cell and proangiogenic cell mobilization in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Sitagliptin exerts an antinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

The metabolic syndrome influences the response to incretin-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0496-4

10.1007/S00592-013-0496-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference